Navigation Links
Hard To Treat Diseases (HTDS.PK) IP Rights Pink Sheets Filings
Date:8/26/2009

SHENZHEN, China, Aug. 26 /PRNewswire-FirstCall/ - Hard to Treat Diseases (the "Company") (HTDS.PK) www.htdsmedical.com provides access to U.S. Patent and Trademark Office.("USPTO") documents relating to intellectual property ("IP") ownership rights of the Company.

HTDS management has duly notified the OTCBB company utilizing the IP rights of the Company and is providing its shareholders with certain other "Supplementary" filings made yesterday with Pink Sheets. The information can be accessed at http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds

The supplementary filings made on Pink Sheets by HTDS include the actual copies of the USPTO recording documents, the letter to the OTCBB Company utilizing HTDS rights and proof of FedEx delivery of the same.

These documents are self explanatory.

HTDS management is of the opinion that this information is material, and both issuers need to disclose its potential effect to its shareholders and investors. The OTCBB company is in default in their filings with the SEC. and has received an "e" on its symbol as a late filing issuer.

HTDS ownership rights for the five patents can be accessed at the following five USPTO websites:

http://assignments.uspto.gov/assignments/q?db=pat qt=pat reel= frame= pat=5223543 pub= asnr= asnri= asne= asnei= asns=

http://assignments.uspto.gov/assignments/q?db=pat qt=pat reel= frame= pat=6743828 pub= asnr= asnri= asne= asnei= asns=

http://assignments.uspto.gov/assignments/q?db=pat qt=pat reel= frame= pat=7241858 pub= asnr= asnri= asne= asnei= asns=

http://assignments.uspto.gov/assignments/q?db=pat qt=pat reel= frame= pat=7321003 pub= asnr= asnri= asne= asnei= asns=

http://assignments.uspto.gov/assignments/q?db=pat qt=pat reel= frame= pat=7476696 pub= asnr= asnri= asne= asnei= asns=

HTDS management will continue to monitor the situation and intends to vigorously escalate its claim to protect its interests. The Company is not ruling out any available options at this point regarding the IP rights that may have a positive significant impact on the entire value of HTDS.

Further updates to follow.

Safe Harbor Statement:

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The Berry Truth: Cystex Know Your Bladder Better Video Explains Why Cranberries Are Great for UTI Prevention, But Not for Treatment
2. Experimental Treatment Could Fight Muscular Dystrophy
3. Long-term tamoxifen use increases risk of an aggressive, hard to treat type of second breast cancer
4. Surgical treatment a rare complication of duodenal diverticulum
5. Introducing anuleaf AD, a New FDA-Approved Hemorrhoid Treatment
6. Treating Prostate Cancer: Old School vs. New School
7. Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN)
8. EndyMed Medical Receives FDA Clearance for Painless, Non-invasive Anti-Wrinkle Treatment System
9. New treatments offer better survival and fresh challenges in colorectal cancer
10. Study finds low risk in treating previously coiled aneurysm
11. Night home hemodialysis shown to be as good as transplant in treating kidney failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Miami native and local periodontist Dr. John ... have never imagined back in 1991 that this journey would have taken me into ... last 25 years, Dr. Gallardo has pioneered implant dentistry innovation, evolving into an internationally ...
(Date:4/26/2017)... ... April 26, 2017 , ... New SUPRO® XT55 ... high-protein beverages by helping beverage manufacturers more effectively manage protein costs. “Soy protein ... savings as well as more stable pricing over time. Now it’s even more ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... topical cream that’s the first in a new class of photodynamic cosmetics (PDC). ... appearance of skin, visibly reduce outward signs of aging, and minimize the appearance ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... committed to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne ... (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced today. , ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... Liberty attempts to compare student test score performance for the 2015-16 school year ... the state’s voucher programs. Though it highlights important patterns in student test score ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... YORK , April 19, 2017 Cardiology devices ... the projected period The Cardiology Devices segment is ... than US$ 15 Mn in 2018 over 2017. By the ... a market valuation close to US$ 700 Mn, expanding at ... Devices segment dominated the Asia Pacific ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 ... Surgical drainage devices are tubes used to remove excess ... include, blood, serum, pus, urine, bile or lymph. Surgical ... types of surgery such as orthopedics surgery, cardiovascular surgery, ... device is prophylactic post-surgery to prevent accumulation of fluid ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
Breaking Medicine Technology: